Michaela Levin's most recent trade in Acrivon Therapeutics Inc was a trade of 130,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 31, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc | Michaela Levin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Michaela Levin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 30,000 | 30,000 | - | 0 | Common Stock |